Craig A. Wheeler Sells 35,666 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 35,666 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total value of $503,247.26. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Craig A. Wheeler also recently made the following trade(s):

  • On Tuesday, November 21st, Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.35, for a total value of $54,948.60.

Shares of Momenta Pharmaceuticals, Inc. (MNTA) opened at $14.75 on Friday. Momenta Pharmaceuticals, Inc. has a twelve month low of $11.85 and a twelve month high of $19.90. The stock has a market capitalization of $1,130.00, a price-to-earnings ratio of -18.44 and a beta of 1.66.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The firm had revenue of $24.09 million during the quarter, compared to the consensus estimate of $29.58 million. During the same period in the prior year, the firm earned ($0.26) EPS. The firm’s quarterly revenue was down 17.3% compared to the same quarter last year. research analysts expect that Momenta Pharmaceuticals, Inc. will post -1.16 EPS for the current year.

A number of research firms have recently commented on MNTA. Barclays restated an “equal weight” rating and set a $16.00 price objective (down from $17.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $14.00 price objective (down from $18.00) on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, December 4th. JPMorgan Chase & Co. restated a “hold” rating and set a $14.00 price objective on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Finally, ValuEngine downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating and ten have assigned a hold rating to the company. The company has an average rating of “Hold” and an average price target of $15.00.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its holdings in Momenta Pharmaceuticals by 14.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 834 shares in the last quarter. Pinebridge Investments L.P. increased its holdings in Momenta Pharmaceuticals by 4.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 363 shares in the last quarter. Profund Advisors LLC increased its holdings in Momenta Pharmaceuticals by 13.1% in the 2nd quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,530 shares in the last quarter. Citigroup Inc. increased its holdings in Momenta Pharmaceuticals by 263.2% in the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 9,954 shares in the last quarter. Finally, Piedmont Investment Advisors LLC acquired a new stake in Momenta Pharmaceuticals in the 2nd quarter valued at $244,000. Hedge funds and other institutional investors own 93.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://transcriptdaily.com/2018/01/05/craig-a-wheeler-sells-35666-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply